The Nocturia Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The Nocturia Global Market has been experiencing a robust growth. It is projected to increase from $2.87 billion in 2024 to $3.11 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.4%.
By 2029, the nocturia market is projected to reach $4.23 billion with a compound annual growth rate (CAGR) of 8.0%.
Download Your Free Sample of the 2025 Nocturia Market Report and Uncover Key Trends Now!The key drivers in the nocturia market are:
• Increasing rate of bladder obstruction disorders and urinary tract inflammation
• Rising incidences of nocturia resulting from various risk factors
• High consumption of fluids leading to nocturia
• Growing awareness of the relationship between nocturia, sleep disorders and kidney health
The nocturia market covered in this report is segmented –
1) By Drug: Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic, Other Drugs
2) By Indication: Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria, Global Polyuria
3) By Causes: Urological Infection, Tumor Of The bladder, Diuretic Medications, Regular Alcohol Or coffee, Liver infection, Diabetes, Pregnancy, Other Causes
4) By End User: Hospitals, Home Care, Clinics
Subsegments:
1) By Anticholinergic Drugs: Oxybutynin, Tolterodine, Solifenacin, Darifenacin, Fesoterodine
2) By Desmopressin: Intranasal Desmopressin, Oral Desmopressin
3) By Antibiotics: Nitrofurantoin, Trimethoprim, Fosfomycin, Other Antibiotics
4) By Antispasmodic: Hyoscine Butylbromide, Flavoxate, Other Antispasmodics
5) By Other Drugs: Alpha-blockers, Beta-3 Agonists, Diuretics, Other Pharmacological Treatments
The key trends in the nocturia market are:
• The application of advanced diagnostics in nocturia treatment is an emerging trend.
• There is a focus on the development of new drugs specific to nocturia.
• Increased research and investment in nocturia treatments are contributing factors.
• Advancements in both surgical and non-surgical treatments, and the adoption of personalized medicine reflect the future trends.
Major players in the nocturia market are:
• Pfizer Inc
• Merck & Co. Inc
• AbbVie Inc
• Sanofi S.A
• GlaxoSmithKline plc
• Viatris Inc
• Boehringer Ingelheim International GmbH
• Otsuka Pharmaceutical Co. Ltd
• Astellas Pharma Inc
• Eisai Co. Ltd.
• Sumitomo Dainippon Pharma Co. Ltd
• Ferring Pharmaceuticals A/S
• Avadel Pharmaceuticals plc
• UroGen Pharma Ltd
• Sanwa Kagaku Co. Ltd.
• Urovant Sciences Inc
• Serenity Pharmaceuticals LLC
• Vantia Therapeutics Inc
• AA Pharma Inc
• Wellesley Pharmaceuticals Inc
North America was the largest region in the nocturia market in 2024